Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Projected CAGR for the Giant-Cell Arteritis Market Size from 2025 to 2034?
The market size for giant-cell arteritis has seen significant expansion in the past few years. The market is predicted to increase from $1.07 billion in 2024 to $1.12 billion in 2025, with a compound annual growth rate (CAGR) of 5.0%. Factors contributing to this historic growth include epidemiological research, genetic discoveries, a rise in the use of biologics, advancements in diagnostic methods, and the creation of targeted therapies and biologics.
In the coming years, the market size of giant-cell arteritis is predicted to experience a stable increase, escalating to $1.34 billion in 2029 with a compound annual growth rate (CAGR) of 4.6%. This boost during the anticipated period is a result of elevated diagnosis rates, an aging populace, increased spending on healthcare, patient advocacy, and proliferation into fresh geographic territories. The period’s defining tendencies encompass advancements in the identification and validation of biomarkers, the creation of therapies directed at specific molecular routes, the adoption of innovative imaging techniques, drug delivery innovations, and the application of AI algorithms for predictive analysis.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Giant-Cell Arteritis Market?
The increasing focus on personalized medicine is projected to fuel the expansion of the giant-cell arteritis market. Personalized treatments involve customizing medical care based on individual traits like genetic profile, lifestyle, and environmental factors. The push for personalized medicine is on the rise, facilitated by progress in genomics, biotechnology, and data analytics. These developments allow for specific therapies that enhance treatment effectiveness and decrease the risk of side effects. Personalized medication could assist in managing giant-cell arteritis (GCA) by enabling treatments tailored to suit individual patient factors like genetic predisposition, immune profiles, and disease presentations. For instance, the U.S.-based non-profit, Personalized Medicine Coalition (PMC), announced in February 2024 that personalized treatments accounted for over a third of new drug approvals by the U.S. Food and Drug Administration (FDA) for the fourth year running in 2023. That year, the FDA sanctioned 16 new customized therapies for rare diseases, a notable increase from the six approvals in 2022. Also, this approval list included seven cancer drugs and three treatments for a variety of other ailments and conditions. Therefore, the surging focus on personalized medicine is propelling the giant-cell arteritis market’s growth.
Which Key Market Segments Comprise the Giant-Cell Arteritis Market and Drive Its Revenue Growth?
The giant-cell arteritismarket covered in this report is segmented –
1) By Therapeutics: Prednisone; Methotrexate; Tocilizumab; Aspirin
2) By Mechanism Of Action: Corticosteroids; Immunosuppressive Agents; Anticoagulants; Other Mechanisms Of Action
3) By Route Of Administration: Oral; Intravenous; Subcutaneous; Other Routes Of Administration
Subsegments:
1) By Prednisone: Oral Prednisone; Intravenous (IV) Prednisone; Low-Dose Prednisone Therapy; High-Dose Prednisone Therapy
2) By Methotrexate: Oral Methotrexate; Subcutaneous Methotrexate; Methotrexate Monotherapy; Methotrexate Combination Therapy
3) By Tocilizumab: Intravenous Tocilizumab; Subcutaneous Tocilizumab; Tocilizumab Monotherapy; Tocilizumab In Combination With Corticosteroids
4) By Aspirin: Low-Dose Aspirin Therapy; Aspirin For Cardiovascular Risk Management; Aspirin In Combination Therapy; Enteric-Coated Aspirin
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=17162&type=smp
Which Areas Are Leading Regions in the Giant-Cell Arteritis Market Expansion Across the Globe?
North America was the largest region in the giant-cell arteritis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theGiant-Cell Arteritis Market Direction?
Major enterprises in the giant-cell arteritis marketplace are innovating with the development of new products, like biosimilars, in an attempt to broaden treatment possibilities and meet the yet unfulfilled healthcare requirements of patients. A biosimilar is a type of biological drug that closely resembles an already existing approved biologic product, with no critical disparities in factors such as safety, effectiveness, and purity. For example, in April 2024, Tocilizumab-aazg was launched in the US by Fresenius SE & Co. KGaA, a healthcare organization headquartered in Germany. The launched product is useful in treating chronic autoimmune disorders such as rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. The said product received its approval based on the data from a randomized, double-blind, single-dose, parallel phase 1 trial that compared its pharmacokinetics, safety, and immunogenicity with the US and EU reference tocilizumab across three patient demographics.
View the full report here:
https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report
How Is the Giant-Cell Arteritis Market Conceptually Defined?
Giant-cell arteritis (GCA) is a type of vasculitis, or inflammation of blood vessels, predominantly affecting medium to large arteries. It commonly involves the temporal arteries, leading to headaches, scalp tenderness, and vision problems. GCA is characterized by inflammation of the vessel walls, potentially leading to serious complications such as blindness or stroke if untreated. Treatment typically involves high-dose corticosteroids to suppress inflammation and prevent complications.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17162
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model